Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

6-Sulfatoxymelatonin predicts treatment response to fluoxetine in major depressive disorder

Texto completo
Autor(es):
Freitas, Juliana Jury [1, 2] ; Xavier, Nicoli Bertuol [1, 2] ; Tonon, Andre Comiran [1, 3] ; Carissimi, Alicia [1, 2] ; Pizutti, Leandro Timm [1, 2] ; Vieira Ilgenfritz, Carlos Augusto [2] ; Markus, Regina Pekelmann [4, 5] ; Hidalgo, Maria Paz [1, 2]
Número total de Autores: 8
Afiliação do(s) autor(es):
[1] Univ Fed Rio Grande do Sul, Programa Posgrad Psiquiatria & Ciencias Comportam, Porto Alegre, RS - Brazil
[2] Univ Fed Rio Grande do Sul, HCPA, Lab Cronobiol & Sono, Porto Alegre, RS - Brazil
[3] HCPA UFRGS, Lab Cronobiol & Sono, Ramiro Barcelos 2350, Sala 21617, BR-90035003 Porto Alegre, RS - Brazil
[4] Univ Sao Paulo, Inst Biociencia, Dept Fisiol, Lab Cronofarmacol, Sao Paulo, SP - Brazil
[5] Univ Fed Rio Grande do Sul, Fac Med, Dept Psiquiatria & Med Legal, Porto Alegre, RS - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY; v. 9, DEC 2019.
Citações Web of Science: 0
Resumo

Background: To date, no biomarker has been able to predict antidepressant response at an early blockade of norepinephrine or serotonin uptake. The transient nocturnal increase in plasma melatonin levels is upregulated by blocking these uptakes. The aim of this study was to test whether fluoxetine increase in urinary 6-sulfatoxymelatonin (aMT6s) is an indicator of serotonin uptake blockade. Methods: A total of 20 women (35-45 years of age) recruited from the community had a diagnosis of major depressive disorder confirmed by the Structured Clinical Interview for DSM-IV. Depressive symptoms were evaluated by the Beck Depression Inventory (BDI). Participants were instructed to take 20 mg of fluoxetine every morning. Every 4 weeks, the dose could be increased by 20 mg until symptom remission. The concentration of aMT6s was evaluated in overnight urine samples collected 1 day before and 1 day after the first fluoxetine dose. Results: An increase in aMT6s correlated to a decrease in BDI score evaluated on day 45 (rho = -0.67, p = 0.024) was observed. Conclusions: Nocturnal increase in urinary aMT6s after the first day of medication use links the early mechanism of action of fluoxetine to its clinical output 45 days later. Thus, the relationship between urinary aMT6s excretion 1 day before/1 day after is a biomarker for predicting clinical output earlier, reducing illness burden and health care costs. (AU)

Processo FAPESP: 13/13691-1 - Eixo imune-pineal: integrando a biologia do tempo em condições fisiológicas, fisiopatológicas e patológicas
Beneficiário:Regina Pekelmann Markus
Linha de fomento: Auxílio à Pesquisa - Temático